Pricing Log in Create free account

NewcelX Ltd. (NCEL) vs TScan Therapeutics, Inc. (TCRX)

NewcelX Ltd. and TScan Therapeutics, Inc. are both Biotechnology companies. NewcelX Ltd. and TScan Therapeutics, Inc. are of similar size ($16.2M and $15.3M). NewcelX Ltd. has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 13 metrics below, NewcelX Ltd. leads on 9 and TScan Therapeutics, Inc. on 4.

Valuation

Metric NCEL TCRX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 4.20 9.71
P/B 4.61 0.43 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.32 0.64
EV/Sales n/m (5.27) 9.21
Earnings yield (61.20%) (395.65%) (33.15%)
Free cash flow yield (17.60%) (396.18%) (25.50%)

Profitability

Metric NCEL TCRX Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin — (1,695.15%) 0.00%
Net margin 0.00% (1,655.35%) 0.00%
Free cash flow margin 0.00% (1,665.18%) 0.00%
Return on equity 0.00% (95.80%) (56.36%)
Return on assets 0.00% (50.09%) (48.04%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric NCEL TCRX Biotechnology median
Revenue growth (TTM) — 2.15% 6.02%
EPS growth (last fiscal year) 11.18% 12.28% 30.26%
Revenue growth, 5-year CAGR — 56.92% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NCEL TCRX Biotechnology median
Debt to equity 0.06 0.47 0.00
Current ratio 0.40 3.37 4.72
Net debt to EBITDA 0.74 0.90 0.96

Dividend

Metric NCEL TCRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NCEL TCRX Biotechnology median
Market cap 15.34m 16.21m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack